Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on developing liver and respiratory rare disease therapeutics. The company leverages three enabling technologies: LUNAR® lipid-mediated delivery, STARR® self-amplifying mRNA (sa-mRNA) technology, and mRNA drug substance and drug product manufacturing expertise. Arcturus developed KOSTAIVE®, a self-amplifying mRNA COVID vaccine that received regulatory approval. The company's clinical pipeline centers on ARCT-032, an inhaled mRNA therapeutic candidate for cystic fibrosis currently in Phase 2, and ARCT-810, an mRNA therapeutic candidate for ornithine transcarbamylase (OTC) deficiency that has completed Phase 2 dosing. Strategic collaborations include Thermo Fisher Scientific for ARCT-032 manufacturing and development, BARDA for pandemic influenza initiatives, and ARCALIS, a Japanese joint venture focused on mRNA vaccine and therapeutics manufacturing. Following the termination of its CSL Seqirus collaboration, Arcturus has regained global rights to KOSTAIVE® and its infectious disease vaccine portfolio spanning seasonal influenza, pandemic influenza, RSV, and EBV programs. The company's versatile RNA therapeutics platforms can be applied to multiple nucleic acid medicine modalities including mRNA, siRNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics, supported by an extensive patent portfolio of over 500 patents and patent applications globally. Updated Aug 6, 2026